Stability of Capecitabine + CDDP + Trastuzumab therapy for HER2-positive advenced gastric cancer

Stability of Capecitabine + CDDP + Trastuzumab therapy for HER2-positive advenced gastric cancer - XPT for HER2-positive AGC

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000007689

Enrollment

Registered

2012-04-08

Start date

2011-07-19

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

gastric cancer

Interventions

chemotherapy

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1) gastric adenocarcinoma (2) unresectable advanced gastric cancer with measurable lesion (3) ingestionable patient of capecitabine (4) Performance Status(ECOG):0-2 (5) over 20 years old (6) more than 3 month prognosis (7) HER2 positive (IHC 3+ or IHC2+ and FISH positive) (8) good heart function (ejection fraction is over 50%) (9) appropriate patient for investigator (10) patient with consent

Exclusion criteria

Exclusion criteria: (1) contraindication of capesitabine, CDDP, and trasutuzmab (2) with seriou conplication (3) innaropriate patient for the investigator (4) less than 50% of LVEF

Design outcomes

Primary

Measure	Time frame
frequency and degre of adverse event	—

Secondary

Measure	Time frame
response rate, disease control rate, time to treatment-failure, progression-free survival	—

Countries

Japan

Contacts

Public ContactNaoyuki Hanari

Graduate school of medicine, Chiba university Frontier surgery

naohana718@faculty.chiba-u.jp043-226-2110

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026